ZEALAND PHARMA/S (NASDAQ:ZEAL) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 15th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last posted its quarterly earnings results on Thursday, August 16th. The company reported ($0.67) earnings per share for the quarter. The business had revenue of $2.42 million for the quarter. ZEALAND PHARMA/S had a negative net margin of 483.00% and a negative return on equity of 78.33%. On average, analysts expect ZEALAND PHARMA/S to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
NASDAQ:ZEAL traded up $0.47 during trading hours on Friday, hitting $13.68. 364 shares of the company’s stock traded hands, compared to its average volume of 8,516. The firm has a market capitalization of $416.68 million, a price-to-earnings ratio of -9.24 and a beta of 2.28. ZEALAND PHARMA/S has a twelve month low of $11.51 and a twelve month high of $18.91.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Recommended Story: Retained Earnings
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.